-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Adverum Biotechnologies Announces Upcoming Data Presentation at AAO 2022
Adverum Biotechnologies Announces Upcoming Data Presentation at AAO 2022
REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that data from the OPTIC trial of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) in wet age-related macular degeneration (wet AMD) will be presented next week during the Late Breaking Developments portion of Retinal Subspecialty Day at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting in Chicago, Illinois. In addition to reviewing the durable efficacy and safety demonstrated out to 104 weeks in the OPTIC Study, the presentation will include new analyses of intraretinal fluid (IRF) and subretinal fluid (SRF) after a single, in-office, intravitreal (IVT) injection of Ixo-vec in subjects requiring frequent anti-VEGF injections for their wet AMD.
Oral Presentation Title: ADVM-022 Intravitreal Gene Therapy for Neovascular AMD: OPTIC Phase 1 Study Update
Session: Late Breaking Developments, Part I
Date & Time: September 30, 2022, 3:39 PM - 3:44 PM EDT
Presenter: Dante Pieramici, M.D., partner, California Retina Consultants
Adverum intends to issue a press release concurrent with the presentation and to post the data presented on the Publications page in the Pipeline section of the company's website.
About Wet Age-Related Macular Degeneration
Wet AMD, also known as neovascular AMD or nAMD, is an advanced form of AMD, affecting approximately 10% of patients living with AMD. Wet AMD is a leading cause of blindness in patients over 65 years of age, with a prevalence of approximately 20 million individuals worldwide living with this condition. The incidence of new cases of wet AMD is expected to grow significantly worldwide as populations age. AMD is projected to impact 288 million people worldwide by 2040, with wet AMD accounting for approximately 10% of those cases.
About OPTIC Trial of ADVM-022 in Wet AMD
ADVM-022, ixoberogene soroparvovec (Ixo-vec), is Adverum's clinical-stage gene therapy product candidate being developed for the treatment of wet AMD. ADVM-022 (Ixo-vec) utilizes a propriety vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. Unlike other ophthalmic gene therapies that require a surgery to administer the gene therapy under the retina (sub-retinal approach) ADVM-022 has the advantage of being administered as a one-time IVT injection in the office and is designed to deliver long-term efficacy and reduce the burden of frequent anti-VEGF injections, optimize patient compliance, and improve vision outcomes for patients with wet AMD.
The OPTIC trial is designed as a multi-center, open-label, dose-ranging, safety and efficacy trial of ADVM-022 (Ixo-vec) in participants with wet AMD who have demonstrated responsiveness to anti-VEGF treatment. Patients in OPTIC are treatment experienced, and previously required frequent anti-VEGF injections to manage their wet AMD and to maintain functional vision.
About Adverum Biotechnologies
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians' offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit .
Corporate & Investor Inquiries
Anand Reddi
Vice President, Head of Corporate Strategy, External Affairs and Engagement
Adverum Biotechnologies, Inc.
T: 650-649-1358
E: areddi@adverum.com
Media
Megan Talon
Associate Director, Corporate Communications
Adverum Biotechnologies, Inc.
T: 650-649-1006
E: mtalon@adverum.com
REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that data from the OPTIC trial of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) in wet age-related macular degeneration (wet AMD) will be presented next week during the Late Breaking Developments portion of Retinal Subspecialty Day at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting in Chicago, Illinois. In addition to reviewing the durable efficacy and safety demonstrated out to 104 weeks in the OPTIC Study, the presentation will include new analyses of intraretinal fluid (IRF) and subretinal fluid (SRF) after a single, in-office, intravitreal (IVT) injection of Ixo-vec in subjects requiring frequent anti-VEGF injections for their wet AMD.
加州雷德伍德城,9月环球通讯社2022年23日电Adverum BioTechnologies,Inc.(纳斯达克:ADVM),一家旨在将基因疗法建立为高度流行眼病护理的新标准的临床阶段公司,今天宣布,ixo-berogene soroparvovec(IXO-VEC,以前称为ADVM-022)在湿性年龄相关性黄斑变性(WAMD)中的眼科试验数据将于下周在伊利诺伊州芝加哥举行的美国眼科学会(AAO)2022年年会视网膜亚专业日的后期突破部分公布。除了回顾在光学研究中展示的104周的持久有效性和安全性外,报告还将包括对需要频繁注射抗血管内皮生长因子治疗湿性AMD的受试者进行单次办公室内玻璃体内(IVT)注射IXO-VEC后视网膜内液(IRF)和视网膜下液(SRF)的新分析。
Oral Presentation Title: ADVM-022 Intravitreal Gene Therapy for Neovascular AMD: OPTIC Phase 1 Study Update
Session: Late Breaking Developments, Part I
Date & Time: September 30, 2022, 3:39 PM - 3:44 PM EDT
Presenter: Dante Pieramici, M.D., partner, California Retina Consultants
口头报告标题:ADVM-022玻璃体腔内基因治疗新生血管性AMD:1期研究最新进展
会话:最新突破发展,第一部分
日期和时间:2022年9月30日下午3:39-美国东部时间下午3:44
主讲人:Dante Pieramici,医学博士,加州视网膜咨询公司合伙人
Adverum intends to issue a press release concurrent with the presentation and to post the data presented on the Publications page in the Pipeline section of the company's website.
Adverum打算在演示的同时发布一份新闻稿,并将在公司网站管道部分的出版物页面上发布数据。
About Wet Age-Related Macular Degeneration
关于湿性老年性黄斑变性
Wet AMD, also known as neovascular AMD or nAMD, is an advanced form of AMD, affecting approximately 10% of patients living with AMD. Wet AMD is a leading cause of blindness in patients over 65 years of age, with a prevalence of approximately 20 million individuals worldwide living with this condition. The incidence of new cases of wet AMD is expected to grow significantly worldwide as populations age. AMD is projected to impact 288 million people worldwide by 2040, with wet AMD accounting for approximately 10% of those cases.
湿性AMD,也被称为新生血管性AMD或NAMD,是AMD的一种高级形式,大约10%的AMD患者受到影响。湿性AMD是65岁以上患者失明的主要原因,全世界约有2000万人患有这种疾病。随着人口老龄化,湿性AMD新病例的发病率预计将在全球范围内显著增长。预计到2040年,AMD将影响全球2.88亿人,其中湿性AMD约占这些病例的10%。
About OPTIC Trial of ADVM-022 in Wet AMD
关于ADVM-022在湿性AMD中的光学试验
ADVM-022, ixoberogene soroparvovec (Ixo-vec), is Adverum's clinical-stage gene therapy product candidate being developed for the treatment of wet AMD. ADVM-022 (Ixo-vec) utilizes a propriety vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. Unlike other ophthalmic gene therapies that require a surgery to administer the gene therapy under the retina (sub-retinal approach) ADVM-022 has the advantage of being administered as a one-time IVT injection in the office and is designed to deliver long-term efficacy and reduce the burden of frequent anti-VEGF injections, optimize patient compliance, and improve vision outcomes for patients with wet AMD.
ADVM-022,Ixo-berogene soroparvovec(IXO-VEC),是Adverum正在开发的治疗湿性AMD的临床期基因治疗产品候选药物。ADVM-022(IXO-VEC)利用专有载体衣壳AAV.7m8,在专有表达盒的控制下携带afLibercept编码序列。与其他需要手术才能在视网膜(视网膜下途径)下实施基因治疗的眼科基因疗法不同,ADVM-022具有在办公室作为一次性IVT注射的优势,旨在提供长期疗效,减轻频繁注射抗血管内皮生长因子的负担,优化患者依从性,并改善湿性AMD患者的视力结果。
The OPTIC trial is designed as a multi-center, open-label, dose-ranging, safety and efficacy trial of ADVM-022 (Ixo-vec) in participants with wet AMD who have demonstrated responsiveness to anti-VEGF treatment. Patients in OPTIC are treatment experienced, and previously required frequent anti-VEGF injections to manage their wet AMD and to maintain functional vision.
OPTION试验是一项多中心、开放标签、剂量范围、安全性和有效性的ADVM-022(IXO-VEC)试验,对象是对抗血管内皮生长因子治疗有反应的湿性AMD患者。OPTEM的患者治疗经验丰富,以前需要频繁注射抗血管内皮生长因子来管理他们的湿性AMD并维持功能性视力。
About Adverum Biotechnologies
关于Adverum生物技术公司
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians' offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit .
Adverum生物技术公司(纳斯达克代码:ADVM)是一家临床阶段的公司,旨在将基因疗法确立为高度流行的眼病的新护理标准,并致力于开发恢复视力和预防失明的功能性疗法。利用其专有的玻璃体内(IVT)平台的研究能力,Adverum正在开发耐用的单次给药疗法,旨在医生办公室提供,以消除治疗这些疾病的频繁眼部注射的需要。Adverum正在评估其新的基因治疗候选药物Ixoberogene soroparvovec(IXO-VEC,以前称为ADVM-022),作为治疗新生血管或湿性年龄相关性黄斑变性患者的一次性IVT注射。通过克服目前这些令人衰弱的眼病的治疗模式带来的挑战,Adverum渴望改变护理标准,保护视力,并在全球范围内产生深远的社会影响。欲了解更多信息,请访问。
Corporate & Investor Inquiries
企业和投资者咨询
Anand Reddi
Vice President, Head of Corporate Strategy, External Affairs and Engagement
Adverum Biotechnologies, Inc.
T: 650-649-1358
E: areddi@adverum.com
阿南德·雷迪
总裁副,企业战略、对外事务和接洽负责人
Adverum生物技术公司
T: 650-649-1358
电子邮箱:areddi@adverticum.com
Media
媒体
Megan Talon
Associate Director, Corporate Communications
Adverum Biotechnologies, Inc.
T: 650-649-1006
E: mtalon@adverum.com
梅根·塔隆
企业传播部助理董事
Adverum生物技术公司
T: 650-649-1006
电子邮箱:mtalon@adverticum.com
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧